(moh-SUN-eh-TOO-zoo-mab)
Mosunetuzumab-axgb works by bringing healthy T cells (immune cells that help kill cancer cells) and lymphoma cells close together so the T cells can more effectively kill the lymphoma cells. It does this by binding to a protein called CD3 on healthy T cells and a protein called CD20 on B cells (the immune cells that are cancerous in B-cell lymphomas). Mosunetuzumab-axgb is a type of targeted therapy drug called a bispecific T-cell engager (BiTE).
FDA label information for this drug is available at DailyMed.
Use in Cancer
Mosunetuzumab-axgb is approved to treat:
- Follicular lymphoma. It is used in adults whose cancer came back or did not respond after at least two other types of systemic therapy.
Mosunetuzumab-axgb is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.
Mosunetuzumab-axgb is also being studied in the treatment of other types of cancer.
More About Mosunetuzumab-axgb
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Mosunetuzumab-axgb – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Mosunetuzumab-axgb – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
